PolyActiva has expanded their Executive Team, appointing Wes Brazell as Chief Financial Officer, and Michael Brubaker, PhD, as Chief Scientific Officer. Their appointments come at an important time for the company, following the recent appointment of Jerry St. Peter as Chief Executive Officer, and Vanessa Waddell continuing in her key leadership role as Chief Strategy Officer.

With this bolstered executive team, PolyActiva is poised to scale globally and advance the lead product candidate, PA5108, into late-stage clinical development.

PolyActiva has announced the next important milestone of our transformational growth – the appointment of seasoned biopharmaceutical executive, Jerry St. Peter, as CEO and Board Director of PolyActiva, following the successful close of our $40M AUD ($25M USD) Series C financing.